FAU’s College of Medicine Awarded $2.1 Million to Study Effectiveness of Medication for Schizophrenia

FAU’s College of Medicine Awarded $2.1 Million to Study Effectiveness of Medication for Schizophrenia

FAU’s College of Medicine Awarded $2.1 Million to Study Effectiveness of Medication for Schizophrenia

BOCA RATON, Fla. (June 30, 2015) — Florida Atlantic University’s Charles E. Schmidt College of Medicine was recently awarded a $2.1 million, two-year contract by Otsuka America Pharmaceutical Inc. to conduct a study to examine the effectiveness of an injectable long-acting antipsychotic medication for schizophrenia and its impact on 30-day hospital readmission rates.

In patients with severe illnesses such as schizophrenia, the risk for relapse and re-hospitalization is substantially increased following hospitalizations. Efforts to promote the use of evidence-based treatments that reduce relapse, improve clinical outcomes and contain health care costs, especially in chronic illnesses, have been a major focus of health quality improvement initiatives in the United States.

Related posts

UNF physics lecturer receives U.S. Patent

Nirmalkumar Patel, a University of North Florida physics associate lecturer, received a U.S. Patent for…

UNF professor reports on returning to exercise post-pandemic, staying healthy in the new year

Dr. James Churilla, UNF professor and Exercise Science and Chronic Disease Graduate Program director, recently…

FIT Biochemist Studies Farming on Mars

Farming on Mars will be a lot harder than ‘The Martian’ made it seem.  Growing…